Pharma Equity Group AS (OCSE:PEG) Total Operating Expense: kr25.29 Mil (TTM As of Dec. 2025)


What is Pharma Equity Group AS Total Operating Expense?

Pharma Equity Group AS OCSE:PEG -3.89% Total Operating Expense is kr25.29 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Pharma Equity Group AS's Total Operating Expense for the six months ended in Dec. 2025 was kr16.72 Mil. Pharma Equity Group AS's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was kr25.29 Mil.

Pharma Equity Group AS Total Operating Expense Related Terms

Pharma Equity Group AS Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Pharma Equity Group AS's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Equity Group AS Total Operating Expense Chart

Pharma Equity Group AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 11.28 25.03 37.48 25.29

Pharma Equity Group AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.09 11.69 25.79 8.57 16.72

Pharma Equity Group AS Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr25.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of kr25.29 Mil mean?
Pharma Equity Group AS (OCSE:PEG) has a Total Operating Expense of kr25.29 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Pharma Equity Group AS and its competitors.
Is Pharma Equity Group AS's Total Operating Expense too high?
Pharma Equity Group AS's current Total Operating Expense is kr25.29 Mil.
How does Pharma Equity Group AS's Total Operating Expense compare to VRTX and REGN?
Pharma Equity Group AS's Total Operating Expense of kr25.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Pharma Equity Group AS and its competitors. Pharma Equity Group AS's current Total Operating Expense is kr25.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current Total Operating Expense of kr25.29 Mil. The current Total Operating Expense is kr25.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current Total Operating Expense is kr25.29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharma Equity Group AS Business Description

Address Slotsmarken 12, 1.th, Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .